Wednesday, June 10, 2026

Patent intelligence · IS

IS 5505

Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju

expired A61K 9/ 00 A IA61K 9/ 06 A IA61K 31/ 19 A IA61K 47/ 00 A I
Status expired
Pipeline programs 1
Years to expiry 0
Applicant portfolio 10
Patent details — IS 5505
Jurisdiction
IS
Status
expired
Grant date
May 23, 2000
Expiration
May 18, 2020
CPC classes
A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 31/ 19 A I, A61K 47/ 00 A I
View on Google Patents ↗

Quick answer

IS 5505 (Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju) is held by ASTELLAS PHARMA EUROP B V [NL]. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 9/ 00 A I, A61K 9/ 06 A I, A61K 31/ 19 A I, A61K 47/ 00 A I, A61K/3119, A61K/90014

More from ASTELLAS PHARMA EUROP B V [NL]

Related pharmaceutical patents in our USPTO index.

  1. CN 120418289

    Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

    ASTELLAS PHARMA EUROPE B V · Expires Jul 27, 2045

    granted
  2. KR 20240032847

    CLDN18.2 및 CD3에 결합하는 이중특이 결합제

    ASTELLAS PHARMA EUROPE B V [NL] · Expires Mar 7, 2044

    granted
  3. CN 105120840

    Composition of tiacumicin compounds

    ASTELLAS PHARMA EUROP B V · Expires Nov 27, 2035

    granted
  4. EP 1549658

    VERBINDUNGEN AUF GLUKOSEBASIS MIT AFFINITÜT FÜR P-SELEKTIN

    YAMANOUCHI EUROP BV [NL] · Expires Jul 1, 2025

    expired
  5. EP 1527086

    VERBINDUNGEN DIE P-SELECTIN BINDEN

    YAMANOUCHI EUROP BV [NL] · Expires Apr 29, 2025

    expired
  6. EP 1423413

    SELEKTIV P-SELECTIN BINDENDE PEPTIDISCHE VERBINDUNGEN

    YAMANOUCHI EUROP BV [NL] · Expires May 28, 2024

    expired
  7. EP 1392755

    ZUSAMMENSETZUNGEN ENTHALTEND LIPID-POLYMER KONJUGATE

    YAMANOUCHI EUROP BV [NL] · Expires Feb 27, 2024

    expired

Frequently asked questions

What is US patent 5505?

IS 5505 (Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju) is held by ASTELLAS PHARMA EUROP B V [NL]. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns IS 5505?

ASTELLAS PHARMA EUROP B V [NL] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.

When does IS 5505 expire?

Our index shows an expiration date of May 18, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.